Abstract. Sepsis is a severe and frequently occurring clinical syndrome, caused by the inflammatory response to infections.
Recent studies on the human transcriptome during sepsis have yielded several gene-expression assays that might assist physicians during clinical assessment of patients suspected of sepsis. SeptiCyte™ LAB (Immunexpress, Seattle, WA) is the first gene expression assay that was cleared by the FDA in the United States to distinguish infectious from non-infectious causes of systemic inflammation in critically ill patients. The test consists of the simultaneous amplification of four RNA transcripts (CEACAM4, LAMP1, PLAC8, and PLA2G7) in whole blood using a quantitative real-time PCR reaction. This review provides an overview of the challenges in the diagnosis of sepsis, the development of gene expression signatures, and a detailed description of available clinical performance studies evaluating SeptiCyte™ LAB.
Pharmacodynamic Modelling of β-lactam/β-lactamase Inhibitor Checkerboard Data: Illustration with Aztreonam–Avibactam
Abstract. Objectives. Checkerboard experiments followed by fractional inhibitory concentration (FIC) index determinations are commonly used to assess ...
Detection and Prevalence of Carbapenem-resistant Gram-negative Bacteria Among European Laboratories Part of the COMBACTE Network: A COMBACTE LAB-Net Survey
Abstract: Antimicrobial resistance (AMR) represents a global public health threat which jeopardizes the progress that modern medicine has made over th...
EURECA - Substudy of Infections Due to Carbapenem-resistant Enterobacteriacea (CRE) Along Europe. Inside COMBACTE Network; Global Information for a Global Problem
IMI Symposium_COMBACTE-CARE_EURECA_Maria Paniagua